Generic Daklinza Deal Sets Precedent In HCV Drug Licensing
This article was originally published in Scrip
Executive Summary
The licensing agreement announced on Nov. 23 by the Medicines Patent Pool and Bristol-Myers Squibb, under which generics firms will be able to manufacture their own versions of the firm's hepatitis C drug daclatasvir for sale in more than a hundred lower-income countries, breaks new ground in several different ways.
You may also be interested in...
Cadila-Hetero Slugfest Over The 'Hep' Tag
Trademark disputes continue unabated in Indian courts, this time involving generic versions of Bristol-Myers Squibb's hepatitis C therapy, Daklinza (daclatasvir) marketed by the local firms Cadila Healthcare and Hetero.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.
EU Warns Of Life-Threatening Interactions Between Paxlovid & Some Immunosuppressants
The EU’s pharmacovigilance committee says that a review of the available evidence showed that in several cases, blood levels of immunosuppressants increased rapidly to toxic levels in patients who were taking the Pfizer drug.